Cancer care has undergone a revolution, driven by advances in the understanding of cancer biology and new therapeutics derived from that understanding. Many patients diagnosed as having cancer in the 1990s received relatively ineffective, toxic chemotherapeutics. Today, a patient encountering an oncologist might undergo a tumor biopsy with the goal of evaluating hundreds of oncogenic mutations. That patient then receives one of the many targeted therapeutics (eg, kinase inhibitors, monoclonal antibodies) or immuno-oncology agents in the ever-expanding therapeutic armamentarium, many developed within the past decade.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sledge GW. Patients and Physicians in the Era of Modern Cancer Care. JAMA. 2019;321(9):829–830. doi:10.1001/jama.2018.17334
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: